After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...

Accelerated-phase CML is characterized by faster progression than chronic phase, with variable symptom burden including fatigue, weight loss, night sweats, bruising, and splenic enlargement.

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

New research into acute myeloid leukemia could change future treatment approaches.

"His bone marrow transplant required a two-month inpatient stay where he wasn't able to step outside or feel fresh air," she ...

Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% ...